Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asim Bilen, Mark N. Stein, Jeffrey Alan Sosman, Robert S. Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David J. Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, David A. Braun, Catherine J. Wu, David Johnson Einstein, Paul J. Catalano, Hans J. Hammers
Institutions: Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Abramson Cancer Center, University of Pennsylvania, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Emory University, Columbia University Irving Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Hackensack University Medical Center, Fox Chase Cancer Center, Cleveland Clinic, Yale University, University of Illinois Chicago, Brigham and Women's Hospital, Harvard University, The University of Texas Southwestern Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Bristol-Myers Squibb
OpenAlex ID: W4213288645